What top creators are saying about Eli Lilly and Company(LLY)

Positioned as an AI agent beneficiary deploying capital to acquire biotech IP and partnering with AI platforms to accelerate discovery.

Positioned to unlock value from dormant IP by deploying multi-agent AI swarms to accelerate drug discovery pipelines.

Adopting frontier AI biological foundation models to scale virtual molecular screening, lower R&D failure rates, and shorten clinical development cycles.

Upcoming obesity drug retatrutide could generate billions as a blockbuster treatment, though microdosing trends, compounding alternatives, and generic competition present potential revenue friction.

Poised to benefit from broader addressable markets as the GLP-1 class expands into multi-indication preventative medicine and longevity applications beyond diabetes and weight management.

Positioned to benefit from an expanding GLP-1 addressable market that extends beyond weight loss and diabetes into broad preventative healthcare, multi-organ disease management, and longevity applications.

Experiencing recent sector-wide stagnation and trades at a 5x to 8x valuation premium relative to telehealth distribution partners.

Cited alongside other large equities as an example of fund managers publicly endorsing stocks aligned with their own investment exposure.

Included in a bullish long basket expected to resolve upward soon rather than consolidate

Target asset accumulated and airdropped to holders via the Peptides meme coin transaction fee mechanism.

Referenced in connection with the trending $PEPTIDES narrative within the meme meta.

Mentioned as a $1T market cap company connected to the biohacking peptides trend

Maintains a strong competitive pipeline in metabolic and anti-obesity drugs, notably with triple-agonist Retatrutide demonstrating approximately 33% weight reduction in Phase 3 trials.

Referenced as a $1.1 trillion market cap company providing narrative backing for the PEPTIDES token.

Gained +1.17% in a two-hour market recovery that is seen with caution as a potential bull trap.

Noted as a $1 trillion company benefiting from peptide interest and tied into a stock/meme coin meta, suggesting a big repricing is imminent.

Introduced Eblis for moderate-to-severe eczema, broadening its dermatology pipeline, though commercial uptake depends on efficacy against established competitors.

Solid long-term healthcare compounder being trimmed or exited by fund managers seeking higher-velocity, cyclical digital asset momentum.

Featured as a primary healthcare asset in the expansion of 24/7 tokenized real-world equity trading on Solana via platforms like Backpack.

Hitting all-time highs powered by massive cash flow from obesity drugs, which is being reinvested into AI-driven discovery and strategic M&A.

Scaling dedicated internal AI data centers to accelerate drug discovery pipelines, supporting strong top-line revenue expansion.

Positioned well in the next-generation metabolic pipeline with triple-hormone agonists like Retatrutide, which show potential in preserving lean muscle mass during rapid weight loss.

Expanded into Solana's tokenized equity market, enabling 24/7 trading, rapid settlement, and utility as on-chain DeFi collateral.

Offers less asymmetric upside in this cycle compared to smaller, data-rich biotech acquisition targets.

Demonstrates strong structural demand and defensive growth potential that historically outperforms tech during inflationary sector rotations.

Gained 3.3% to reach a new all-time high and a $1.2 trillion market cap on strong pharma sector momentum.

Investor reports significant short-term profits on long positions and anticipates the company reaching a $2T valuation after breaking all-time highs.

Reached fresh all-time highs above $1,278, advancing 4% to 5% amid strong macro rotation into healthcare.

Ebglus approval expands Lilly's footprint into the multibillion-dollar atopic dermatitis market, providing a key growth driver alongside its core diabetes and obesity franchises.

Features robust fundamental quality with ~50% YoY sales growth, a 32% return on invested capital, and minimal share dilution at a 25x forward P/E.

Bullish on LLY citing a $220k profit over the past week and a target of a $2T valuation.

Positioned as an application-layer beneficiary leveraging AI advancements.

Successfully beat earnings reports, viewed as a preferred angle for the AI trade, and has a specific price target of $5 trillion.

Eli Lilly demonstrated clear dominance in the diet drug wars, posting strong earnings and remaining the clear market leader in the GLP-1 weight-loss drug market.

Included in long positions alongside IBB

Mentioned as a potential acquirer or major player through its direct-to-consumer initiative LillyDirect.

Smashed earnings this week and represents one of the author's biggest stock positions.

Reported Q2 2026 earnings beating estimates with revenue of $23.0B and adjusted EPS of $8.38, and raised full-year 2026 guidance.

Delivered a strong revenue beat driven by surging demand for its class-leading drug portfolio, serving as a stable healthcare holding.

Considered a strong long-term investment due to high demand for weight loss and metabolic drugs like RETRA-2, supported by robust R&D spending and NVIDIA-powered AI drug discovery.

Driving massive success in the pharmaceutical sector behind GLP-1 weight-loss drugs.

Announced plans to officially file for regulatory approval of its oral retatrutide drug in the first quarter of 2027.

Using AI to accelerate drug discovery, resulting in an unnatural competitive advantage and positioning the company to outpace peers.

Viewed as an AI trade due to the intersection of AI and healthcare/drug discovery.

Identified as a target for investors rotating capital into high-quality software/product names.

Facing disruption risk from biologics due to the Black Box Warning and lack of durable effect after treatment cessation for Olumiant.

Part of the high-growth GLP-1 market moving toward oral delivery and combination therapies for weight loss and inflammation.

Described as a decade-long trade based on consumer biotech demand.

Monopoly on GLP-1 patents and effectively using AI for drug modeling; viewed as a rotation hedge with high-conviction buy status.

Healthcare leader expected to benefit from AI application layer productivity gains.